Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Names Pfizer’s Brandicourt Healthcare Division CEO

This article was originally published in The Pink Sheet Daily

Executive Summary

The broadly experienced pharmaceutical executive – who has specialized particularly in emerging markets and infectious diseases – inherits a healthcare division that is in the midst of several product launches and has few near-term patent expirees.

You may also be interested in...



Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella

Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.

Pfizer Shuffle: Simmons Out, Brandicourt In At Emerging Markets And Established Products Unit

David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel